Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Madrigal Pharmaceuticals ( (MDGL) ).
On January 29, 2026, Madrigal Pharmaceuticals and Roche amended their long-standing research, development, and commercialization agreement, giving Madrigal full and exclusive control over all patent term adjustments and extensions related to Rezdiffra, including those on patents owned by Roche or jointly held. In return, Madrigal agreed that royalties paid to Roche on net sales of Rezdiffra will remain at current levels and will not be reduced until certain existing or potential patent term extensions expire, a move that strengthens Madrigal’s strategic control over a key asset while maintaining Roche’s royalty economics for a longer period, with implications for both companies’ revenue visibility and IP positioning around Rezdiffra.
The most recent analyst rating on (MDGL) stock is a Buy with a $587.00 price target. To see the full list of analyst forecasts on Madrigal Pharmaceuticals stock, see the MDGL Stock Forecast page.
Spark’s Take on MDGL Stock
According to Spark, TipRanks’ AI Analyst, MDGL is a Neutral.
The score is held back primarily by ongoing unprofitability and negative free cash flow despite strong revenue growth and gross margins. Technicals are a meaningful positive with a strong uptrend and solid momentum. Earnings-call updates reinforce strong launch traction and strategic progress, while valuation remains pressured due to losses and the absence of an earnings-based support.
To see Spark’s full report on MDGL stock, click here.
More about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies, including its liver disease drug Rezdiffra, targeting significant unmet medical needs in its market.
Average Trading Volume: 354,023
Technical Sentiment Signal: Buy
Current Market Cap: $11.28B
See more insights into MDGL stock on TipRanks’ Stock Analysis page.